STAAR SURGICAL CO — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
STAAR Surgical reported Q3 2026 net sales of $83.4M (down 12% YoY, but up 21% excluding $25.9M deferred China sales from Q3 2025). Nine-month sales reached record $270.5M. Net income Q3: $5.6M ($0.11 EPS); 9M: $18.8M ($0.37 EPS). Company completed manufacturing transition to Switzerland for China-bound ICLs (reducing US-China tariff exposure), appointed new Chief Commercial Officer David Bailey, initiated clinical trials for next-generation presbyopia products, and Board authorized $50M share repurchase program.
Why this rating
Record 9M revenue and strong cash position ($206.4M, no debt) are positive; buyback signals confidence. Tariff mitigation and R&D pipeline expansion meaningful. But Q3 revenue decline, gross margin pressure (70.9% vs 82.2% prior year), and China sales down 30% YoY show near-term headwinds. Event represents meaningful execution milestone relative to ~$884M market cap, not transformational.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.